Alendronic Acid

證據等級: L5

預測適應症: 0 個

Alendronic Acid: Drug Repurposing Evaluation — No Candidate Indications Identified

One-Sentence Summary

Alendronic acid is a nitrogen-containing bisphosphonate widely used clinically for the treatment and prevention of osteoporosis and Paget’s disease of bone. The current Evidence Pack (version v4, data cutoff 2026-04-04) contains no TxGNN-predicted repurposing candidates, making a standard repurposing evaluation impossible at this stage. Two blocking data gaps — UK regulatory labelling and mechanism of action data — must be resolved before this assessment can progress.

Quick Overview

Item	Content
Original Indication	Not recorded in this Evidence Pack
Predicted New Indication	None identified
TxGNN Prediction Score	N/A
Evidence Level	L5 — No predictions generated
UK Market Status	Not recorded in this Evidence Pack
Number of Marketing Authorisations	0 (as recorded in Evidence Pack)
Recommended Decision	Hold

⚠️ Data Quality Notice: This Evidence Pack is materially incomplete. Alendronic acid (DrugBank DB00630) is a well-established bisphosphonate with multiple MHRA-authorised products in the UK (e.g., Fosamax, and numerous generics). The absence of licensing records and original indication data in the Evidence Pack strongly suggests a data ingestion failure upstream, rather than a true absence of authorisation. This must be investigated and corrected before any repurposing analysis is meaningful.

UK Market Information

No marketing authorisation records were returned by the Evidence Pack pipeline for the United Kingdom.

Action required: Verify MHRA product licence data for Alendronic acid via the MHRA Product Licence Search and re-run the data ingestion pipeline. Multiple PL numbers are expected for 70 mg weekly tablets and 10 mg daily tablets across numerous manufacturers.

Safety Considerations

No safety data (warnings, contraindications, or drug interactions) was returned in this Evidence Pack.

Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack is too incomplete to support any repurposing evaluation — there are no predicted indications, no original indication records, no UK regulatory data, and no safety information. This reflects upstream pipeline failures rather than a genuine absence of data for this widely licensed drug.

To proceed, the following is needed:

[Critical — DG001] Retrieve and parse the UK SmPC (MHRA-approved labelling) for Alendronic acid to populate approved indications, warnings, and contraindications
[Critical — DG002] Query DrugBank API (DB00630) to retrieve mechanism of action, pharmacodynamics, and drug interaction data
[Critical] Re-run the MHRA product licence ingestion pipeline and confirm PL records are correctly retrieved; verify that market_status and total_licenses fields are populated
[Critical] Re-run the TxGNN prediction pipeline; confirm that predicted_indications is populated with at least one candidate before generating a repurposing report
[Recommended] Once predictions are available, cross-reference with NICE technology appraisals and BNF bone metabolism drug category (BNF Chapter 6.6) for contextual relevance

This report is generated for research purposes only and does not constitute medical advice. Any drug repurposing candidate identified by TxGNN requires clinical validation before application. All findings should be interpreted in the context of current clinical guidelines and regulatory requirements.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.